Multiparametric Evaluation in Differentiating Glioma Recurrence from Treatment-Induced Necrosis Using Simultaneous ¹⁸F-FDG-PET/MRI: A Single-Institution Retrospective Study

REFERENCES

1. 1.↵
   2. Chamberlain MC,
   3. Glantz MJ,
   4. Chalmers L, et al

   . Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007;82:81–83 doi:10.1007/s11060-006-9241-y pmid:16944309

   CrossRefPubMed
2. 2.↵
   2. Brandes AA,
   3. Franceschi E,
   4. Tosoni A, et al

   . MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26:2192–97 doi:10.1200/JCO.2007.14.8163 pmid:18445844

   Abstract/FREE Full Text
3. 3.↵
   2. Chan JL,
   3. Lee SW,
   4. Fraass BA, et al

   . Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002;20:1635–42 doi:10.1200/JCO.20.6.1635 pmid:11896114

   Abstract/FREE Full Text
4. 4.↵
   2. Sugahara T,
   3. Korogi Y,
   4. Tomiguchi S, et al

   . Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000;21:901–09 pmid:10815666

   Abstract/FREE Full Text
5. 5.↵
   2. Brandsma D,
   3. Stalpers L,
   4. Taal W, et al

   . Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453–61 doi:10.1016/S1470-2045(08)70125-6 pmid:18452856

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Alexiou GA,
   3. Tsiouris S,
   4. Kyritsis AP, et al

   . Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities. J Neurooncol 2009;95:1–11 doi:10.1007/s11060-009-9897-1 pmid:19381441

   CrossRefPubMed
7. 7.↵
   2. Heiss W,
   3. Raab P,
   4. Lanfermann H

   . Multimodality assessment of brain tumors and tumor recurrence. J Nucl Med 2011;52:1585–600 doi:10.2967/jnumed.110.084210 pmid:21840931

   Abstract/FREE Full Text
8. 8.↵
   2. Keunen O,
   3. Taxt T,
   4. Grüner R, et al

   . Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. Adv Drug Deliv Rev 2014;76:98–115 doi:10.1016/j.addr.2014.07.010 pmid:25078721

   CrossRefPubMed
9. 9.↵
   2. Wang X,
   3. Hu X,
   4. Xie P, et al

   . Comparison of magnetic resonance spectroscopy and positron emission tomography in detection of tumor recurrence in posttreatment of glioma: a diagnostic meta-analysis. Asia Pac J Clin Oncol 2015;11:97–105 doi:10.1111/ajco.12202 pmid:24783970

   CrossRefPubMed
10. 10.↵
    2. Nihashi T,
    3. Dahabreh IJ,
    4. Terasawa T

    . Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR Am J Neuroradiol 2013;34:944–50, S1–11 doi:10.3174/ajnr.A3324 pmid:23124638

    Abstract/FREE Full Text
11. 11.↵
    2. Huang RY,
    3. Neagu MR,
    4. Reardon DA, et al

    . Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy: detecting illusive disease, defining response. Front Neurol 2015;6:33 doi:10.3389/fneur.2015.00033 pmid:25755649

    CrossRefPubMed
12. 12.↵
    2. Estrada G,
    3. González-Maya L,
    4. Celis-López MA, et al

    . Diagnostic approach in suspected recurrent primary brain tumors using (18)FDG-PET/MRI, perfusion MRI, visual and quantitative analysis, and three dimensional stereotactic surface projections: first experience in Mexico. Rev Esp Med Nucl 2008;27:329–39 doi:10.1157/13126189 pmid:18817662

    CrossRefPubMed
13. 13.↵
    2. Seeger A,
    3. Braun C,
    4. Skardelly M, et al

    . Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease. Acad Radiol 2013;20:1557–65 doi:10.1016/j.acra.2013.09.003 pmid:24200483

    CrossRefPubMed
14. 14.↵
    2. Di Costanzo A,
    3. Scarabino T,
    4. Trojsi F, et al

    . Recurrent glioblastoma multiforme versus radiation injury: a multiparametric 3-T MR approach. Radiol Med 2014;119:616–24 doi:10.1007/s11547-013-0371-y pmid:24408041

    CrossRefPubMed
15. 15.↵
    2. Enslow MS,
    3. Zollinger LV,
    4. Morton KA, et al

    . Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med 2012;37:854–61 doi:10.1097/RLU.0b013e318262c76a pmid:22889774

    CrossRefPubMed
16. 16.↵
    2. Nozawa A,
    3. Rivandi AH,
    4. Kanematsu M, et al

    . Glucose-corrected standardized uptake value in the differentiation of high-grade glioma versus post-treatment changes. Nucl Med Commun 2015;36:573–81 doi:10.1097/MNM.0000000000000288 pmid:25714806

    CrossRefPubMed
17. 17.↵
    2. Ellingson BM,
    3. Kim HJ,
    4. Woodworth DC, et al

    . Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 2014;271:200–10 doi:10.1148/radiol.13131305 pmid:24475840

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Kim ES,
    3. Satter M,
    4. Reed M, et al

    . A novel, integrated PET-guided MRS technique resulting in more accurate initial diagnosis of high-grade glioma. Neuroradiol J 2016;29:193–97 doi:10.1177/1971400916639962 pmid:27122050

    CrossRefPubMed
19. 19.↵
    2. Peca C,
    3. Pacelli R,
    4. Elefante A, et al

    . Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? Clin Neurol Neurosurg 2009;111:331–34 doi:10.1016/j.clineuro.2008.11.003 pmid:19117668

    CrossRefPubMed
20. 20.↵
    2. Hygino Da Cruz LC,
    3. Rodriguez I,
    4. Domingues RC, et al

    . Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011;32:1978–85 doi:10.3174/ajnr.A2397 pmid:21393407

    Abstract/FREE Full Text
21. 21.↵
    2. Garibotto V,
    3. Heinzer S,
    4. Vulliemoz S, et al

    . Clinical applications of hybrid PET/MRI in neuroimaging. Clin Nucl Med 2013;38:e13–18 doi:10.1097/RLU.0b013e3182638ea6 pmid:23242058

    CrossRefPubMed
22. 22.↵
    2. Prager AJ,
    3. Martinez N,
    4. Beal K, et al

    . Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol 2015;36:877–85 doi:10.3174/ajnr.A4218 pmid:25593202

    Abstract/FREE Full Text
23. 23.↵
    2. Ozsunar Y,
    3. Mullins ME,
    4. Kwong K, et al

    . Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging. Acad Radiol 2010;17:282–90 doi:10.1016/j.acra.2009.10.024 pmid:20060750

    CrossRefPubMed
24. 24.↵
    2. Deng SM,
    3. Zhang B,
    4. Wu YW, et al

    . Detection of glioma recurrence by ¹¹C-methionine positron emission tomography and dynamic susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun 2013;34:758–66 doi:10.1097/MNM.0b013e328361f598 pmid:23670103

    CrossRefPubMed
25. 25.↵
    2. Gahramanov S,
    3. Raslan AM,
    4. Muldoon LL, et al

    . Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 2011;79:514–23 doi:10.1016/j.ijrobp.2009.10.072 pmid:20395065

    CrossRefPubMed
26. 26.↵
    2. Fink JR,
    3. Carr RB,
    4. Matsusue E, et al

    . Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects. J Magn Reson Imaging 2012;35:56–63 doi:10.1002/jmri.22801 pmid:22002882

    CrossRefPubMed
27. 27.↵
    2. Matsusue E,
    3. Fink JR,
    4. Rockhill JK, et al

    . Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 2010;52:297–306 doi:10.1007/s00234-009-0613-9 pmid:19834699

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Mong S,
    3. Ellingson BM,
    4. Nghiemphu PL, et al

    . Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol 2012;33:1763–70 doi:10.3174/ajnr.A3053 pmid:22538078

    Abstract/FREE Full Text
29. 29.↵
    2. Werner P,
    3. Rullmann M,
    4. Bresch A, et al

    . Impact of attenuation correction on clinical [(18)F]FDG brain PET in combined PET/MRI. EJNMMI Res 2016;6:47 doi:10.1186/s13550-016-0200-0 pmid:27255510

    CrossRefPubMed
30. 30.↵
    2. McGirt MJ,
    3. Woodworth GF,
    4. Coon AL, et al

    . Independent predictors of morbidity after image-guided stereotactic brain biopsy: a risk assessment of 270 cases. J Neurosurg 2005;102:897–901 doi:10.3171/jns.2005.102.5.0897 pmid:15926716

    CrossRefPubMedWeb of Science